Synaptogenix Inc (SNPX) - Total Assets
Based on the latest financial reports, Synaptogenix Inc (SNPX) holds total assets worth $19.79 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Synaptogenix Inc for net asset value and shareholders' equity analysis.
Synaptogenix Inc - Total Assets Trend (2018–2024)
This chart illustrates how Synaptogenix Inc's total assets have evolved over time, based on quarterly financial data.
Synaptogenix Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Synaptogenix Inc's total assets of $19.79 Million consist of 99.9% current assets and 0.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 99.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Synaptogenix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Synaptogenix Inc (SNPX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Synaptogenix Inc's current assets represent 99.9% of total assets in 2024, unchanged from 99.9% in 2018.
- Cash Position: Cash and equivalents constituted 99.6% of total assets in 2024, up from 97.9% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Synaptogenix Inc Competitors by Total Assets
Key competitors of Synaptogenix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Synaptogenix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 20.51 | 2.98 | 22.40 |
| Quick Ratio | 20.51 | 2.98 | 22.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $18.82 Million | $18.47 Million | $27.83 Million |
Synaptogenix Inc - Advanced Valuation Insights
This section examines the relationship between Synaptogenix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.18 |
| Latest Market Cap to Assets Ratio | 0.46 |
| Asset Growth Rate (YoY) | -43.0% |
| Total Assets | $17.73 Million |
| Market Capitalization | $8.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values Synaptogenix Inc's assets below their book value (0.46x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Synaptogenix Inc's assets decreased by 43.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Synaptogenix Inc (2018–2024)
The table below shows the annual total assets of Synaptogenix Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $17.73 Million | -43.00% |
| 2023-12-31 | $31.11 Million | -19.41% |
| 2022-12-31 | $38.61 Million | +8.68% |
| 2021-12-31 | $35.52 Million | +426.21% |
| 2020-12-31 | $6.75 Million | -62.28% |
| 2019-12-31 | $17.90 Million | -39.28% |
| 2018-12-31 | $29.48 Million | -- |
About Synaptogenix Inc
TAO Synergies Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X synd… Read more